Comparing two medicines for severe eye inflammation in Behçet's disease
Treatments studied
Part of Eyes & vision, Immune system & allergy clinical trials.
This study compares two biologic medicines, adalimumab and tocilizumab, to see which works better for severe eye inflammation (uveitis) caused by Behçet's disease. Both are given as injections, and the goal is to improve vision and reduce eye damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You need a diagnosis of Behçet's disease (or a history of mouth or genital sores) and have uveitis in the middle or back of your eye that threatens your sight.
- You must not have active tuberculosis, other severe infections, HIV, hepatitis B or C, or certain other serious health conditions.
- You must have had a chest X-ray or CT scan within the last 12 weeks showing no active tuberculosis or other infection.
- If you could become pregnant or father a child, you must agree to use effective birth control during treatment and for several months after.
- You must not be pregnant or breastfeeding and must be willing to stop certain other immune-suppressing drugs before starting the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called adalimumab, which helps calm the immune system, when added to the steroid medicine you may already be taking. It aims to see if this combination is safe and works better for people with Behçet's disease that affects the back of the eye and has recently flared up.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This study tests an injection called adalimumab (Tebiovio®) to see if it helps control inflammation in the eyes of adults with non-infectious uveitis. It might be a good option if you are already on steroid pills and looking for another treatment.
This study tests if ustekinumab or apremilast can help control Behçet's disease symptoms like mouth and genital ulcers, skin sores, and joint pain. It may be an option if standard treatments haven't worked well.
Hear when a new Behcet's Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.